- Patients
- Clinical Research
- Clinical trials
- MAHOGANY
Lymphoma
MAHOGANY
A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Trial overview
Haemotology
Lymphoma
III
St Andrew's Precinct (Oncology)
Level 1, 337 South Terrace, Adelaide, SA, 5000, Australia
(08) 8228 6700 infooncologysa@genesiscare.comDisclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.